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ABSTRACT
There are several characteristics of stem cells that make them unique in
comparison with other mammalian cells. First, they exist as unspecialized cells
lacking tissue-specific characteristics and they maintain this undifferentiated
phenotype until exposed to appropriate signals. Second, they have the capacity
for extensive self-renewal. Third, under the influence of local biological signals
they can differentiate into specialized cells with a phenotype fully distinct from
that of the precursor. Mesenchymal stem cells in the bone marrow apparently
conform to this definition. These cells, as their name implies, are the precursors of
cells of mesenchymal lineage, including cartilage, bone, fat, muscle, and tendon.
They are easily isolated from bone marrow and adipose tissue and from several
other sources. At this point we have an incomplete understanding of the regulation
of differentiation, commitment, and plasticity of the mesenchymal cell population
isolated from marrow. We can identify several of the signals that activate the cells
to differentiate along specific cell pathways and we can describe the phenotype of
the fully differentiated cells, but we understand little of the intermediate steps. In
addition, we know nothing about the reversibility of these pathways or the ability
of differentiated cells to revert to a stem cell phenotype. Nor do we understand
transdifferentiation or the ability of cells to differentiate horizontally from one
lineage to another. Furthermore, there is little clarity surrounding the niche, or
tissue-specific microenvironment, in which the cells reside. Despite the lack of
understanding of these cells and their natural history, it is clear that they have
therapeutic potential in a broad variety of clinical applications. There are many
disease targets for which mesenchymal stem cell therapy is being assessed in both
preclinical and clinical studies. This article assesses our current understanding of
the natural history of mesenchymal cell populations in marrow and other tissues,
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their control, proliferation, and differentiation, and attempts to assess accurately
the status of their therapeutic evaluation in different diseases.
KEYWORDS:Mesenchymal stem cells, transplantation, cell therapy, tissue
engineering, wound repair
Mesenchymal stem cells (MSCs) were first
isolated from rat bone marrow by Friedenstein and
coworkers.1 They described the isolation and ex-
pansion in culture of adherent fibroblastic cells and
their differentiation to osteocytes. They noted the
appearance of colonies of cells in culture and de-
duced that each colony was derived from a single
precursor, or colony-forming unit. The term col-
ony-forming unit–fibroblastic (CFU-F) is often
used in this context. Friedenstein’s work has re-
ceived somewhat less attention than it deserved, and
it was some time before the magnitude of his
contribution was realized. Now, however, we fully
acknowledge the debt we owe and appreciate his
insight into progenitor cell populations in bone
marrow. Over the past decade there has been an
explosion of information that has added to our
understanding of stem cell biology. In many
ways it was possible to learn from the efforts
of hematopoietic stem cell (HSC) biologists
two decades earlier, especially in the technical and
experimental approaches used. However, at this
point MSCs are still less well understood than
HSCs and in some ways these cells have not been
fully defined.
MSCs reside within the stromal compart-
ment of bone marrow. They have the capacity to
differentiate into cells of connective tissue lineages,
including bone, fat, cartilage, and muscle. They also
provide the stromal support system for hematopoi-
esis. Although they represent a very small fraction of
the total population of nucleated cells in marrow,
they can be isolated and expanded with high effi-
ciency and induced to differentiate under well-
defined culture conditions. These cells have gener-
ated a great deal of interest because of their poten-
tial use in regenerative medicine. Although the
therapeutic testing of these cells has progressed
well, there are still many questions to be addressed
concerning the role of endogenous populations of
stem cells in the adult and the function of various
stem cell niches. In addition, there are several
aspects of the implanted cell-host interaction that
need to be addressed as we attempt to understand
the mechanisms underlying these therapies. Of
particular importance are the host immune response
to implanted cells, homing mechanisms that dir-
ect these cells to a site of injury, and their differ-
entiation under the influence of host-derived
signals. This article describes the characteristics of
MSCs and provides some examples of clinical ap-
proaches in MSC therapy that are being evaluated.
ISOLATION AND EXPANSION OF
MESENCHYMAL STEM CELLS
MSCs represent about 0.0001% of the total pop-
ulation of nucleated cells in marrow. Despite their
rarity, they can be isolated and expanded with
efficiency and induced to differentiate to multiple
lineages under defined culture conditions. They are
generally isolated from an aspirate of bone marrow
harvested from the superior iliac crest of the pelvis
in humans. In larger animals2–5 marrow is often
obtained from the same site, and in rodents it is
generally harvested from the mid-diaphysis of the
tibia or femur. Although they represent a minor
fraction of the total nucleated cell population in
marrow, MSCs can be plated and enriched using
standard cell culture techniques. Frequently, the
whole marrow sample is subjected to fractionation
on a density gradient solution such as Percoll, after
which the cells are plated at a density of about
1.6 105 cells/cm2. Cells are generally cultured in
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basal medium such as Dulbecco’s modified Eagle’s
medium (high glucose) in the presence of 10% fetal
bovine serum.6 One of the technical challenges
regarding the isolation and culture expansion of
human MSCs (and those of other species) is this
dependence on fetal bovine serum. This has a more
serious element because it is also batch specific. This
means that certain batches of sera give better results
than others. Little is known about the detailed
composition of positive sera, but a serum screen is
often recommended. Because the large-scale culture
of cells depends on the availability of suitable
batches of sera, this is a strategic impediment in
the commercialization of stem cell therapy. The
second major obstacle in the use of MSCs for
human therapy arises because of the risk of disease
transmission, such as transmission of the variant
form of Creutzfeldt-Jakob disease.
Because of these problems, several investiga-
tors have looked at alternatives to bovine serum for
MSC expansion. Lennon et al7 reported on the
development of a serum-free medium for rat MSCs,
but little advance has been made in the development
of a serum-free medium for human cells. An alter-
native approach in the clinical delivery of cells has
been the use of autologous patient serum. A study
performed by Stute et al8 indicated that the addition
of 10% autologous serum allowed the expansion and
osteogenic activation of bone marrow–derived
MSCs in a manner that was comparable with fetal
bovine serum. This is an encouraging result, and
this question will certainly be studied by others. In
the meantime, the issue of serum-free media con-
ditions for the preparation of cells for human use is
one that will continue to affect the development of
clinically acceptable protocols.
MSCs in culture have a fibroblastic morphol-
ogy and adhere to the tissue culture substrate
(Fig. 1). In fact, their adherent nature serves as a
functional definition of phenotype. Primary cultures
are maintained for 12 to 16 days, during which time
the HSC population is depleted. The addition of
growth factor supplements such as fibroblast growth
factor-2 (FGF-2) to primary cultures of human
MSCs was reported by Martin et al9 to lead to an
enhanced osteogenic potential. Although this effect
was not observed with murine MSCs,10 the addi-
tion of FGF-2 is associated with the selection of
cells with increased telomere length.11
Phinney et al10 reported substantial variation
in the yield and level of expression of alkaline
phosphatase in MSCs prepared from different
strains of inbred mice. They also noted the persis-
tence of CD45þ and CD11bþ pre–B cell progen-
itors and granulocytic and monocytic precursors in
these cultures. Nonetheless, a fraction of these
adherent cells represented true MSCs, as shown
by osteogenic and adipogenic activity. These obser-
vations led to the development of useful methods
involving CD34/CD45/CD11b immunodepletion
to generate purified MSC preparations.12
Further characterization of the conditions
required for culturing progenitor cells from murine
and rat bone marrow was performed by Jiang et al.13
These authors found that murine, but not human,
cells required leukemia inhibitory factor (LIF) for
expansion. Further, they reported that rat cells
required epidermal growth factor (EGF) and pla-
telet-derived growth factor-BB (PDGF-BB) in
addition to LIF, conditions similar to those re-
quired for embryonic stem cells. The cells, referred
to as multipotent adult progenitor cells (MAPCs),
were found to have the capacity to differentiate into
cells with mesodermal, neuroectodermal, and endo-
dermal characteristics in vitro and, when injected
into an early blastocyst, gave rise to most somatic
cell types. These observations indicated that the
plasticity of cell populations in the marrow is greater
than previously understood. In an attempt to under-
stand the effect of different culture protocols on cell
phenotype, Lodie et al14 performed a systematic
comparison of cells isolated from human marrow
and cultured in either 10% FBS, 0.5% FBS supple-
mented with FGF-2, or 2% FBS supplemented
with EGF and PDGF-BB. These authors reported
little functional difference between the cells isolated
by any protocol, in terms of surface marker expres-
sion and differentiation potential. Taken together,
these results illustrate the complexity of subpopu-
lations of bone marrow cells, the need to evaluate
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Figure 1 Undifferentiated mesenchymal stem
cells grown in monolayer culture (A) and after
differentiation along the osteogenic (B), adipogenic
(C), and chondrogenic pathways (D and E). Cell
differentiation in these cultures was observed fol-
lowing staining with von Kossa (B), Nile red O (C),
and Safranin O (D) and by immunostaining with an
antibody specific for type II collagen (E). From Barry
and Murphy.15
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isolation techniques with care, and the need to
identify new cell-specific markers.
DIFFERENTIATION
The differentiation of MSCs into bone, cartilage,
and fat has been well described. Osteogenic differ-
entiation occurs when cells are cultured in a mono-
layer in the presence of b-glycerol-phosphate,
ascorbic acid-2-phosphate, dexamethasone, and
fetal bovine serum (Fig. 1B). Differentiation is
accompanied by an alteration in morphology, upre-
gulation of alkaline phosphatase activity, and the
elaboration of a mineralized extracellular matrix.
The ideal culture environment for the induc-
tion of chondrogenesis of MSCs consists of a three-
dimensional culture format, serum-free medium,
and the presence of a member of the transforming
growth factor-b (TGF-b) superfamily (Fig. 1D–E).
Under these conditions, the cells undergo a rapid
and dramatic morphological change and begin to
express several cartilage-specific extracellular matrix
components. This is accompanied by a rapid accu-
mulation of glycosaminoglycan. TGF-b1, b2, and
b3 have the ability to induce this response, and
TGF-b2 and b3 are more effective than b1 in
promoting chondrogenesis.16 This may relate to
the abundance of these isoforms in bone and
their role in fracture callus formation and wound
healing.
MSCs cultured in monolayer in the presence
of isobutylmethylxanthine become adipocytes with
the production of large lipid-filled vacuoles
(Fig. 1C). Adipogenic differentiation of MSCs is
induced by the nuclear receptor and transcription
factor, peroxisome proliferator-activated receptor-g
(PPAR-g), as well as fatty acid synthetase. Both
interleukin-1 and tumor necrosis factor-a suppress
adipogenesis, and this is mediated through nuclear
factor-B (NF-B) activated by the TAK1/TAB1/
NF-B induction kinase cascade.17 The effect of
inhibition by these cytokines is to direct differ-
entiation toward osteogenesis.
Differentiation toward a myoblast pheno-
type, induced by 5-azacytidine, was reported by
Taylor and Jones for embryonic and adult cells18
and by Wakitani et al for rat stromal cells.19
Phinney et al found that exposure of mouse
MSCs to amphotericin B, but not 5-azacytidine,
resulted in the formation of multinucleated fibers
resembling myotubes.10 There are other examples of
in vivo differentiation associated with therapeutic
delivery. Gussoni et al20 showed that murine
MSCs, injected into the quadriceps muscle of mdx
mice, expressed dystrophin in association with the
muscle fiber sarcolemma, and they pointed toward a
potential therapy for muscular dystrophy. Toma
et al21 injected b-galactosidase–expressing human
MSCs into the left ventricle of CB17 SCID/beige
adult mice and found the labeled cells dispersed
throughout the myocardium and expressing desmin,
cardiac-specific troponin T, a-actinin and phospho-
lamban, all indicative of differentiation of the en-
grafted cells to a mature myocardial phenotype.
Induction of mouse, and human MSCs along
the neurogenic pathway has been described.22–27
Treatment of MSCs with isobutylmethylxanthine
and dibutyryl cyclic AMP induced expression of
early markers of neuronal differentiation,26 as did
EGF or brain-derived neurotrophic factor (BDNF)
in a neuronal growth medium.25 Transdifferentia-
tion of mouse marrow stromal-derived mature
osteoblasts and the stromal cells themselves to a
neural phenotype was achieved by treatment with
5-azacytidine in the presence of nerve growth
factor, BDNF, and neurotrophin-3.27 Treatment
of rat cells with dimethyl sulfoxide/butylated hy-
droxyanisole in the presence of basic FGF and
PDGF was also successful in inducing a neural
phenotype.22,23
THERAPEUTIC APPLICATIONS OF
MESENCHYMAL STEM CELLS
Stem cell therapy involves the transplantation of
autologous or allogeneic stem cells into patients,
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through either local delivery or systemic infusion.
There is a precedent in HSC transplantation, which
has been used for some years in the treatment of
leukemia and other cancers.28 Some striking exam-
ples of the therapeutic use of marrow-derived
MSCs have been reported. These address a broad
spectrum of indications, including cardiovascular
repair, treatment of lung fibrosis, spinal cord injury,
and bone and cartilage repair. Orlic et al29 showed
that locally delivered bone marrow cells can gen-
erate de novo myocardium, indicating that stem cell
therapy can be useful in treating coronary artery
disease. Stamm et al30 demonstrated the practical
utility of this approach in a study involving the
delivery of bone marrow cells into the infarct zone
in patients following myocardial infarction. The
result of this treatment was a dramatic improvement
in global heart function. Deb et al31 have also shown
engraftment of bone marrow–derived cardiomyo-
cytes in the adult heart following bone marrow
transplantation. Saito et al32 demonstrated that
MSCs are tolerated in a xenogeneic environment
while retaining their ability to be recruited to the
injured myocardium and undergo differentiation to
a cardiac phenotype.
MSCs have also been shown by Ortiz et al12
to engraft at high levels in lung tissue following
exposure to bleomycin and to offer protection
against bleomycin-induced lung injury, including
inflammation and collagen deposition. These ob-
servations have broad implications in the area of
lung disease associated with environmental damage.
Stem cells with the ability to differentiate
into neurons, astrocytes, and oligodendrocytes have
been isolated from rat spinal cord,33 and implanta-
tion of neural stem cells in an adult rat model of
spinal cord injury resulted in long-term functional
improvement.34 Embryonic stem cells are capable of
forming dopamine neurons in an animal model of
Parkinson’s disease.35 The ability of bone marrow–
derived stem cells to differentiate into neural line-
ages in vitro and after transplantation in both mice
and rats has been evaluated by Sanchez-Ramos,24
leading to the conclusion that they may be useful
in the treatment of stroke, traumatic injury, and
Parkinson’s disease. Furthermore, it was demon-
strated by Mezey et al that adult human bone mar-
row cells can enter the brain and generate neurons
after transplantation.36 These and other equally
dramatic observations underlie much of the current
excitement and optimism about the use of stem cell
therapy in the treatment of neuronal injury.
In the area of orthopedic medicine there are
also many examples of applications involving local
delivery of marrow stem cells. These include spine
fusion,37 the repair of segmental bone defects,38 and
craniotomy defects.39 Similar approaches have
also been described for the repair of focal defects
in articular cartilage.40,41 In an animal model of
osteoarthritis (OA) involving injury to the menis-
cus, delivery of stem cells by intra-articular injection
resulted in engraftment of those cells on the me-
niscus, fat pad, and synovium with regeneration
of meniscal tissue and protection of the cartilage.5
The chondroprotective effects seen in these
studies apparently derive from the regenerated me-
niscus because there is no evidence of direct engraft-
ment of the implanted cells on the fibrillated
cartilage.
There is accumulating evidence of the hypo-
immunogenic nature of MSCs, and this has broad
implications in terms of allogeneic therapy or the
delivery to a recipient of cells derived from an
unmatched donor. There are several reports describ-
ing the clinical use of allogeneic donor–mismatched
cells with little evidence of host immune rejection or
graft-versus-host disease (GVHD). For example,
allogeneic bone marrow transplantation in children
with osteogenesis imperfecta resulted in engraft-
ment of donor-derived MSCs and an increase in
new bone formation.42 Infusion of allogeneic MSCs
into patients with Hurler’s syndrome or metachro-
matic leukodystrophy showed no evidence of allor-
eactive T cells and no incidence of GVHD.43
Engraftment of allogeneic MSCs has also been
demonstrated in a patient with severe idiopathic
aplastic anemia with improvement of marrow stro-
mal function.44 Tables 1 and 2 summarize in vivo
studies involving preclinical or clinical evaluation of
MSC therapy in several disease targets.
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STEM CELL EXHAUSTION
IN DISEASE
It is interesting to consider that certain degenerative
conditions, where there is progressive tissue damage
and an inability to repair, may be due to the fact that
stem cell populations are depleted or functionally
altered. This has been considered in the case of OA,
a disease of the joints in which there is progressive
and irreversible loss of cartilage, with changes also
Table 1 Testing of Mesenchymal Stem Cell Therapy (MSC) in Animal Models of Disease
Indication
Animal Model/Route
of Delivery MSC Source Result Reference
Myocardial infarction Mouse/direct injection Linc-kitþ bone marrow
cells
De novo myocardium 29
Myocardial infarction Immunocompetent Lewis
rats/IV injection I week
before infarction
C57B1/6 mouse MSCs Donor-derived
cardiomyocytes and
angiogenesis
32
Muscular dystrophy mdx mouse/IV injection Normal mouse
muscle-derived MSCs
Partial restoration of
dystrophin expression
in affected muscle
20
Lung fibrosis Bleomycin (BLM)-sensitive
C57BL/6 mouse/ IV injection
BLM-resistant BALB/c
mouse
Reduced inflammation
and collagen deposition
12
Spine fusion Canine bone marrow–derived
cells/cancellous bone matrix
Autologous Improved bone grafting 37
Segmental bone
defects
Athymic rat/ceramic carrier
Canine/ceramic carrier
Human MSCs
Autologous MSCs
Enhanced bone formation
and improved biomechanics
45
Canine/ceramic carrier Allogeneic MSCs Enhanced bone formation 46
Enhanced bone formation 47
Craniotomy defect Immunocompromised
mouse/gelatin sponge
Alloplastic transgenic mouse
marrow stromal cells
> 99% repair within 2 weeks 39
Tendon defect Rabbit/contracted collagen
gel
Autologous MSCs Improved tendon biomechanics,
structure, and function
48
Meniscus Caprine/intra-articular injection Autologous MSCs Enhanced tissue formation
and reduced osteoarthritis
5
From Barry and Murphy.59
Table 2 Clinical Evaluation of Mesenchymal Stem Cells (MSCs)
Indication
Source/Route
of Delivery Result Reference
Myocardial infarction AC133þ bone marrow
cells/direct injection
Function enhanced in 4 of 6 and
tissue perfusion improved
strikingly in 5 of 6 patients
49
Osteogenesis imperfecta Allogeneic bone marrow
transplantation/infusion
New dense bone formation and engraftment
of donor-derived cells in 3 patients
42
Large bone defect Autologous bone marrow
stromal cells/scaffold
Enhanced bone repair in 1
of 1 patient
38
Metachromatic leukodystrophy
(MLD) and Hurler syndrome
Allogeneic MSCs/infusion Significant improvements in nerve
conduction velocities in 4 of 6 MLD
patients. No graft-versus-host disease.
43
Severe idiopathic aplastic anemia Allogeneic MSCs/infusion Improved stroma in 1 of 1 patient 44
From Barry and Murphy.59
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in the underlying bone. In a study described by
Murphy et al,50 MSCs were prepared from marrow
taken from patients with end-stage OA undergoing
joint replacement surgery. The marrow samples
were harvested both from the site of surgery (either
the hip or the knee) and from the iliac crest. It was
found that the proliferative capacity of the cells was
substantially reduced in the osteoarthritic patients,
and this was independent of the site of harvest. In
addition, the chondrogenic and adipogenic activity
of the cells was significantly reduced, again inde-
pendent of the site of marrow harvest. These effects
were apparently disease related and not age related,
but additional studies are necessary to confirm these
preliminary observations. However, the data lead to
an attractive notion that susceptibility to OA or
other degenerative diseases may be due to the
reduced mobilization or proliferation of stem cells,
and, even if mobilized, the cells may have a limited
capacity to differentiate, leading to defective tissue
repair. This may be a simple interpretation, and the
altered stem cell activity may also be interpreted as a
response of the cells to the disease environment,
specifically the elevated levels of inflammatory cy-
tokines seen in OA. Further, the effect of anti-
inflammatory drugs on cell activity needs to be
taken into account.
HOST IMMUNE RESPONSE TO
ALLOGENEIC TRANSPLANTATION
Several studies have suggested that MSCs are
immunosuppressive or hypoimmunogenic51–56 with
allogeneic transplantation to an immunocompetent
host possible. MSCs may in fact play a role in
enabling alloantigen tolerance.42,43 Present at
low levels in HSC transfers, they are considered
to be immunosuppressive, and human MSCs
can promote unrelated HSC survival and suppress
T cell activation in a nonobese diabetic–severe com-
bined immunodeficiency (NOD-SCID) model.57
Numerous therapeutic possibilities based on this
immunosuppressive effect have been proposed.58
Using bone marrow–derived allogeneic Flk-1 Sca-
1 MSCs in a mouse model, Deng et al not only
demonstrated long-term tolerance of allogeneic skin
grafts but also provided data suggesting the induc-
tion of hematopoietic chimerism.59 Aggarwal and
Pittenger demonstrated that human MSCs modu-
late allogeneic immune responses60 and supported
the tolerance of allogeneic MSCs. There is a broad
body of data using different cells, different species,
and diverse readouts all supporting the description
of MSCs as being exceptions to the regular alloge-
neic rejection mechanisms. These findings have
been seen with human cells, with rat and mouse
cells, and even in xenogeneic mixed lymphocyte
reaction.51,61–64
It is clear that a broad body of data supports
the description of MSCs as being exceptions to the
regular allogeneic rejection mechanisms. Two ques-
tions arise out of these observations. First, how do
MSCs mediate this effect? This gap in our under-
standing has prompted the focus of research to the
discovery of mechanisms by which hypoimmuno-
genicity is maintained. Two mechanisms have been
evoked, one involving direct cell-cell interaction,
the other requiring the secretion of immunomodu-
latory factors. The second question relates to the
mechanism by which allogenic MSCS escape im-
mune detection and is more difficult to approach.
Nonetheless, these are questions of critical impor-
tance that must be addressed before we can proceed
with the widespread use of allogeneic MSCs in
therapy.
CONCLUSION
It seems that MSC therapy is likely to be both
effective and safe for use in several disease targets,
but there are still many questions to be answered
regarding the fate of transplanted cells and the
mechanism of repair. It is necessary to continue to
study the pharmacokinetics of transplanted cells and
mechanisms of engraftment, homing, and in vivo
differentiation. Chronic toxicology studies will also
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be necessary as the clinical use of these cells becomes
widespread. It is clear that MSCs present many
fascinating opportunities for the study of stem cell
differentiation, plasticity transdifferentiation, en-
graftment, and homing. Another exciting develop-
ment is the use of stem cells as vehicles for the
delivery of therapeutic genes. As the safety profile
of stem cells is more fully understood and more
advanced and safer gene vectors are developed,
it may be that the combination of stem cell and
gene therapy is a powerful new approach for the
treatment of several diseases that are currently
untreatable.
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